FeesSafety
Pluang+

Desert Hawk Gold sells 427 oz gold, 935 oz silver in Q3 2026 with gold at $4,276/oz average price.

Market News
15 Sep 2026
PRNewsWire
View Source
Neutral
Desert Hawk Gold sells 427 oz gold, 935 oz silver in Q3 2026 with gold at $4,276/oz average price.

Desert Hawk Gold Corp. reported sales of 427 ounces of gold and 935 ounces of silver from June to August 2026. The average gold price during this period was $4,276 per ounce, while silver averaged $63.19 per ounce. The company also noted 1,701 recoverable ounces remain on its leach pad as of August's end. These figures reflect ongoing production and sales performance amid fluctuating metal prices.

Clifton Mining Company's September 2026 report is presented here with relevant market data for context. For readers following Basic Materials stocks, here is Pluang's market snapshot as of Sep 15, 2026 16:51 WIB: of 32 priced US stocks, 10 rose and 20 fell. Notable prices include ArcelorMittal SA at USD 73.29 (+0.69%), Gold Fields Limited at USD 42.86 (-0.60%), and Air Products & Chemicals, Inc. at USD 285.43 (-0.59%).

More News

Canada's Royal Canadian Legion launches 2026 Poppy Campaign with new contactless donations and a commemorative mural.

Canada's Royal Canadian Legion launches 2026 Poppy Campaign with new contactless donations and a commemorative mural.

The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...

Others
Bullish
2 hours ago
XBiotech appoints Jan-Paul Simard as Co-CEO alongside Sushma Shivaswamy to strengthen leadership.

XBiotech appoints Jan-Paul Simard as Co-CEO alongside Sushma Shivaswamy to strengthen leadership.

XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...

Market News
Bullish
2 hours ago
XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs to lead antibody therapy development.

XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs to lead antibody therapy development.

XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...

Market News
Bullish
2 hours ago
Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte launch trial combining petosemtamab and INCB161734 for KRAS G12D metastatic colorectal cancer.

Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...

Company Fundamentals
Bullish
4 hours ago
Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix reports promising Phase 1 results for JNJ-1900 in advanced melanoma resistant to anti-PD-1 therapies

Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...

Company Fundamentals
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App